The Patent Finder

Allgenesis Biotherapeutics Inc.

8 patents currently held · Updated Nov 21, 2026
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
May 2036
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Feb 15, 2027
    The maintenance fee for VEGFR fusion protein pharmaceutical composition (US 11,723,955) comes due Feb 15, 2027. Unpaid by Aug 16, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 8 of 8

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 10,154,994Ophthalmic Formulations of Tyrosine Kinase Inhibitors, Methods of Use Thereof, and Preparation Methods Thereof
In force
 · High confidence
In forceHigh confidence
US 11,369,600Ophthalmic Formulations of Tyrosine Kinase Inhibitors, Methods of Use Thereof, and Preparation Methods Thereof
In force
 · High confidence
In forceHigh confidence
US 10,870,635Compounds and their use as BACE1 inhibitors
In force
 · USPTO record
In forceUSPTO record
US 11,192,927Fusion Proteins for Inhibiting Angiogenesis
In force
 · High confidence
In forceHigh confidence
US 12,152,057Fusion Proteins for Inhibiting Angiogenesis
In force
 · High confidence
In forceHigh confidence
US 10,961,203Crystalline forms of 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-phenylamino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone
In force
 · USPTO record
In forceUSPTO record
US 11,723,955VEGFR fusion protein pharmaceutical composition
In force
 · USPTO record
In forceUSPTO record
US 12,318,428VEGFR fusion protein pharmaceutical composition
In force
 · USPTO record
In forceUSPTO record
Also on record, not counted in the 8: 1 patent in force now held by others. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 pending · 2 abandoned · 2 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited